<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140751</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA-030</org_study_id>
    <secondary_id>KALESOLO</secondary_id>
    <nct_id>NCT00140751</nct_id>
  </id_info>
  <brief_title>Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients</brief_title>
  <acronym>KALESOLO</acronym>
  <official_title>A 48-Weeks National Multicenter Randomized Open Clinical Trial Evaluating Tolerance and Efficacy of a Treatment Simplification by Lopinavir/Ritonavir Versus Continuation of Current Treatment in HIV-Infected Patients With a Viral Load Inferior to 50 Copies/mL Since 6 Months At Least</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and tolerance of a treatment
      simplification by a Lopinavir/ritonavir monotherapy versus continuation of current treatment
      in HIV-infected patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Highly active antiretroviral therapy (HAART) has made a significant impact on the natural
      history of HIV-1 infection, but toxicities and complexities of therapy limit long-term
      efficacy, and make simpler yet effective HAART regimens highly desirable. Previous attempts
      to 'de-intensify' protease inhibitor (PI)-based therapy by discontinuing reverse
      transcriptase inhibitors (RTI) after achieving viral suppression met with failure, probably
      because plasma levels of most individually administered PI are too low to inhibit viral
      replication consistently.

      Low-dose ritonavir substantially enhances lopinavir plasma levels, and lopinavir/ritonavir
      (LPV/r) is effective as part of a combination therapy in both naive and PI-experienced
      patients. Furthermore, lopinavir is known to have a high genetic barrier to selection of
      resistance. LPV/r monotherapy could thus have the right combination of potency, favorable
      pharmacokinetics, and high genetic barrier needed to suppress viral replication and prevent
      the selection of lopinavir resistance. Preliminary results with &quot;maintenance&quot;LPV/r
      monotherapy show interesting results but data from randomized studies are needed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a viral load &lt; 50 copies/mL at S48 without any modification of antiretroviral treatment during study</measure>
    <time_frame>W48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of viral response</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of lymphocytes CD4</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological tolerance</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative and qualitative changes in quality of life data</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-efficacy ratio</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of proviral DNA before treatment simplification</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients showing a lipodystrophy at J0 and S48</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Simplification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients included in this arm are on Monotherapy of Kaletra (Lopinavir/ritonavir)during 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients included in this arm continue their treatment without any changes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir (drug)</intervention_name>
    <arm_group_label>Simplification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 18 years

          -  Confirmed HIV-1 seropositivity

          -  Antiretroviral treatment stable since 3 months at least

          -  HIV-1 ARN load &lt; 50 copies/mL since 6 months at least

          -  Signed consent form

          -  No history of treatment failure (= viral load &gt; 1000 copies/mL) including a protease
             inhibitor

          -  No opportunistic infection in the previous 6 months

        Exclusion Criteria:

          -  Neutrophils &lt; 750/mm3

          -  Hemoglobin &lt; 8 g/dL

          -  Platelets &lt; 60,000/mm3

          -  Creatinin &gt; 150 micromoles/L

          -  SGOT &gt; 5 NUL (Normal Upper Limit)

          -  SGPT &gt; 5 NUL

          -  Current IL-2 treatment

          -  HBV infection treated or not by lamivudine or tenofovir

          -  Pregnancy or feeding

          -  Enrollment in another study not compliant with KALESOLO Study group assignment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc MEYNARD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Antoine - Service des Maladies Infectieuses et Tropicales (Paris, France)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pierre Zobda-Quitman - Service de Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Fort-de-France</city>
        <state>Martinique</state>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Région Annecienne (CHRA) - Service d'Infectiologie</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier - Unité de Maladies Infectieuses</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin - Service de Médecine Interne et Maladies Infectieuses</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André - Service de Médecine Interne et Maladies Infectieuses</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André - Service de Médecine Interne et Maladies Tropicales</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Côte de Nacre - Service des Maladies Infectieuses</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor - Service d'Immunologie Clinique</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré - Service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital A. Michallon - Service des Maladies Infectieuses</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre - Service de Médecine Interne</name>
      <address>
        <city>Le Kremlin-Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord - CISIH</name>
      <address>
        <city>Marseille</city>
        <zip>13020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte-Marguerite - Unité Médicale CISIH</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac - Service de Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet - Service d'Infectiologie</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine - Service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière - Service de Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière - Service de Médecine Interne 1</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital-Fondation Saint-Joseph - Service des Maladies Infectieuses</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou (HEGP) - Département d'Immunologie</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon - Service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou - Service des Maladies Infectieuses</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil - Hôpital de Jour du CISIH - Clinique Médicale A</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gustave Dron - Service des Maladies Infectieuses</name>
      <address>
        <city>Tourcoing</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Brabois Adultes - Service de Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.imea.fr/</url>
    <description>Click here for more information about this study: KALESOLO</description>
  </link>
  <reference>
    <citation>Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003 Jul 5;362(9377):22-9.</citation>
    <PMID>12853195</PMID>
  </reference>
  <reference>
    <citation>Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14;292(2):251-65.</citation>
    <PMID>15249575</PMID>
  </reference>
  <reference>
    <citation>Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001 Jul 27;15(11):1369-77.</citation>
    <PMID>11504958</PMID>
  </reference>
  <reference>
    <citation>Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60.</citation>
    <PMID>9516219</PMID>
  </reference>
  <reference>
    <citation>Murphy R, Gazzard B. Antiretroviral treatment guidelines. AIDS. 2003 Jun;17 Suppl 2:S1.</citation>
    <PMID>12870522</PMID>
  </reference>
  <reference>
    <citation>Bucher HC, Kofler A, Nüesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS. 2003 Nov 21;17(17):2451-9.</citation>
    <PMID>14600516</PMID>
  </reference>
  <reference>
    <citation>Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002 Nov 15;35(10):1219-30. Epub 2002 Oct 21. Review.</citation>
    <PMID>12410482</PMID>
  </reference>
  <reference>
    <citation>Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999 May 7;13(7):805-10.</citation>
    <PMID>10357379</PMID>
  </reference>
  <reference>
    <citation>Moyle G, Baldwin C, Mandalia S, Comitis S, Burn P, Gazzard B. Changes in metabolic parameters and body shape after replacement of protease inhibitor With efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort. J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):399-401.</citation>
    <PMID>11707680</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>September 18, 2013</last_update_submitted>
  <last_update_submitted_qc>September 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Treatment simplification</keyword>
  <keyword>Lopinavir/ritonavir</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>HIV Seropositivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

